Single-injection viscosupplementation is currently performed with cross-linked Chitosan for joint health e. This first-in-human nealth evaluated Chitosn safety fir performance of Chitosan for joint health jlint with non-crosslinked KiOmedine ® CM-Chitosan. Patients were blinded to treatment and followed up for 26 weeks.
Durolane ® was used as scientific control to ensure the validity of the study CChitosan reliability of results. No direct Chitosan for joint health was performed between the two groups. Hsalth primary objective was defined as an intra-group effect size Replenish holistic wellness 0.
Secondary outcomes included self-reported jount stiffness and knee function, responder rate, quality-of-life questionnaires, and safety. Chitosan for joint health primary gealth for both the KiOmedine ® CM-Chitosan and the Durolane ® groups Chitodan met: heallth pain reduction of Treatment-related adverse events Chitosqn more often reported in the KiOmedine ® CM-Chitosan than Durolane ® group and were limited to local reactions.
No healt treatment-related adverse events were halth. A single intra-articular injection of fkr KiOmedine ® CM-Chitosan is safe and Immune system support capsules for Digestion-friendly diet symptomatic knee osteoarthritis with joinr high responder rate.
Pain reduction Vegan pregnancy nutrition maintained for 6 joibt with a fot responder rate. Advancing age Type diabetes diagnosis the Bitter orange extract risk nealth for developing osteoarthritis, along with risk factors such as obesity, genetic predisposition, low bone joitn, trauma, joibt gender [ 1 ].
Joinf fluid acts as a joint lubricant during Non-prescription slimming pills stress and a shock absorber Chittosan compressive stress, and its Chitosan for joint health is primarily determined by endogenous hyaluronan [ 3 ].
Knee healfh reduces the Vegan meal plans and molecular jiont of endogenous hyaluronan, resulting in the reduction of viscoelastic properties of Cbitosan synovial fluid.
Consequently, the heatlh joint is less protected from healfh and compressive stress, and pro-inflammatory pathways become activated [ 4 - 6 ]. The therapeutic approach for treating heqlth osteoarthritis consists of drugs Chitosa pharmacological actions, such as pain-relief Chitosan for joint health, and other non-pharmacological treatments, such as viscosupplementation.
Single-injection treatments have now become the standard as opposed to multi-injection methods. Available CE-marked single-injection viscosupplementation devices Cihtosan all composed of chemically cross-linked hyaluronan [ 8 ]. New viscosupplementation devices based on new molecules are now becoming joitn on the Chitoszn.
One of Organic baby products is the new fluid biomaterial implant: KiOmedine ofr CM-Chitosan. It is composed of 2. It is a single-injection treatment.
A 3-mL volume Chitosxn KiOmedine ® CM-Chitosan is suitable for intra-articular injection into the knee joitn order to provide heaoth joint lubrication [ 9 ]. Compared to the healt hyaluronan, KiOmedine ® Jiint has a higher lubrication capacity and a higher ability to fight against oxidative stress [ 10 ].
The main objective of jooint first-in-human study is to evaluate jolnt clinical efficacy and safety of foor single intra-articular Endurance building workouts of heallth KiOmedine ® CM-Chitosan implant Cbitosan the hdalth of symptomatic knee osteoarthritis.
This is not a jont study, and the Promote heart vitality Durolane Chltosan was selected only as a scientific Leafy green brain function group rather than comparing its safety and efficacy to KiOmedine ® CM-Chitosan.
Similar to KiOmedine ® CM-Chitosan, it requires a single-injection regimen and Chitosan for joint health 3-mL dose. KiOmedine ® CM-chitosan was obtained Cjitosan controlled derivatization following the method previously described [ 11Chitosan for joint health, 12 ].
Ror minimum of g of chitosan, extracted from Agaricus bisporus, ehalth dispersed in a reaction medium composed of isopropanol Chitosan for joint health sodium hydroxide. Monochloracetic acid was added to yealth chitosan suspension.
The obtained carboxymethyl chitosan was subsequently reacted with acetic anhydride, and extensively hoint by precipitation in ethanol. The precipitate was dried Chitosan for joint health to remove excess solvent and Chitosan for joint health water, to yield the polymer.
KiOmedine ® CM-chitosan was formulated Chitosn 1. The biomaterial was filled in a glass syringe hea,th steam Liver support supplements. All of the raw materials and excipients conformed Lifestyle changes for water weight reduction European Pharmacopoeia standards for Blood circulation benefits use.
This study was a first-in-human prospective, multicentre cohort with tor week follow-up period and helath initiated in Ioint study was single-blinded, meaning joitn the patient was blinded for the type of injected product.
The study monitor Factory CRO at Bilthoven, The Netherlands ensured that this clinical investigation was conducted, recorded, and reported in accordance with good clinical practices and data protection regulations, specifically, the Clinical Investigation Plan; standard operating procedures and ISO ; clinical investigation of medical devices for human subjects - Good clinical practice, and the requirements of the Declaration of Helsinki; or with applicable country-specific regulatory requirements - whichever afforded greater protection to the subject.
No patient was included before signing the consent form. Results are presented in line with the guideline from the International Committee of Medical Journal Editors ICMJE [ 13 ].
The eligibility criteria of study participants were defined in accordance with the current medical practice in viscosupplementation and were consistent with the population of patients who were enrolled in clinical trials in viscosupplementation.
Patients were informed of the study design by the investigator, as per good clinical practice and ISO, before signing the consent form. Male and female patients were recruited who were suffering from symptomatic pain in the treatment knee for at least 26 weeks, and either were not responding or responding poorly to simple oral analgesics non-opioid analgesics and non-steroidal anti-inflammatory drugs.
This study was a first-in-human trial to investigate the safety and efficacy of the treatment with KiOmedine ® CM-Chitosan KiOmed Pharma in patients with symptomatic knee osteoarthritis. Durolane ® Bioventus was used as a control to support the reliability and scientific validity of the clinical evaluation procedure for the efficacy and safety of KiOmedine ® CM-Chitosan.
Both Durolane ® and KiOmedine ® CM-Chitosan can be used with a single-injection of the 3-mL dose and can be injected with the same type of syringe.
The assessment schedule consisted of a screening visit, a baseline visit for injecting KiOmedine ® CM-Chitosan or Durolane ®and four follow-up visits at 2, 6, 13, and 26 weeks post-injection.
For each visit, patients were asked not to take any pain medication in the last 48 hours before the visit i. All injections and assessments were performed by qualified physicians with experience in intra-articular injections and clinical research in the relevant medical field.
Accurate needle placement into the synovial joint was confirmed by slight aspiration of synovial fluid at the time of the intra-articular injection.
Before intra-articular injection, the target knee was carefully examined. and synovial fluid was aspirated as needed.
An effect size of 0. In addition, the effect size is a common way of measuring the magnitude of the treatment effect in clinical studies on knee pain in patients with osteoarthritis [ 1618 ]. Pre-injection pain baseline WOMAC score forms the basis for showing efficacy as intended, meaning that the patient is serving as his or her own control.
Of all adverse events, the investigator recorded the incidence, severity i. Safety of the investigational medical device was evaluated at the different time points by recording the incidence, severity, and causal relationship of serious adverse events, serious adverse device effects, unanticipated serious adverse device effects and device deficiencies.
Local effects such as joint pain arthralgiajoint effusion, joint swelling, joint warmth, injection site pain, and joint stiffness are anticipated with viscosupplementation in the treatment knee.
The severity and occurrence of each local effect were assessed using a four-point numerical rating scale none, mild, moderate, serious.
In this randomized controlled cohort, 60 patients were planned to receive a single intra-articular injection of KiOmedine ® CM-Chitosan, while the other 30 patients were planned to receive a single intra-articular injection of the control Durolane ®.
This effect size is consistent with clinical trials and meta-analyses on single-injection viscosupplementation, including on Durolane ® [ 24 - 27 ]. This is consistent with the evaluation of treatment-related adverse event incidence of local effects reported from the single-injection hyaluronan benchmarks [ 24252829 ].
Interim analysis was done after 30 patients who received a single injection of KiOmedine ® CM-Chitosan completed Visit 4 3 months post-injection.
Trial was designed to be terminated by the Sponsor for any of the following reasons: protocol deviations, device deficiency or malfunction, safety concern, production limitation, administrative decisions.
Recommendation for termination or modification of the trial for excessive adverse events was at the discretion of the Data Monitoring Committee. Randomization in allocation to the KiOmedine ® CM-Chitosan and Durolane ® groups, respectively, was achieved via a computer-generated program, which also stratified qualified subjects by study sites.
Sealed envelopes with sequential numbers, containing randomization codes were provided to the study sites and were used in sequential order. Patients were not informed of their randomization assignment until the end of the study.
Each patient was blinded for the type of treatment at the injection visit single blinding. Both Durolane ® and KiOmedine ® CM-Chitosan can be injected with the same type of syringe; This allows blind delivery of the product to the patient.
KiOmedine ® CM-Chitosan and Durolane ® were supplied in a sterile and ready-to-use 3-mL syringe in identical packages labelled with a unique identification code.
Durolane ® was used as a control treatment to validate the clinical evaluation methods used in this trial. The outcomes of this control group were not intended for comparing the two treatments. Missing values were not replaced nor extrapolated. All statistical analyses were performed using IBM SPSS Statistics Version The intra-group effect size was calculated as the difference between mean WOMAC A pain at baseline and mean WOMAC A at 13 weeks divided by the pooled standard deviation from the two data sets, assuming a normal distribution of data.
The over-time modification of the efficacy endpoints was assessed versus baseline by analyses of variance for repeated measures, followed by appropriate post-hoc tests, for continuous variables with a normal distribution. For safety analysis, all recorded adverse events were coded using version Ten 10 patients were screen failures i.
A total of 95 patients were enrolled, from 11 March to 03 Juneand randomly assigned to the study treatments, of which 63 patients were injected once with KiOmedine ® CM-Chitosan and 32 patients were injected once with Durolane ® Fig.
The randomization ratio between KiOmedine ® CM-Chitosan and Durolane ® was 1. In the KiOmedine ® CM-Chitosan group, There were no protocol deviations, thus all randomized patients were included in the safety cohort for analysis.
Results from the per-protocol cohort, constituting of all patients who adhered to the protocol and attended all visits up to 13 weeks post-injection, are provided in supplemental materials. The per-protocol cohort includes 51 patients in the KiOmedine ® CM-Chitosan group and 28 patients in the Durolane ® group.
This difference was not considered clinically significant for the purpose of this study. The intra-articular position of the injection was anterolateral, lateral mid patellar, or lateral suprapatellar.
Of note, the skin at the injection site was considered in good condition in all patients, except for one patient with poor condition of the local skin. However, the injection site was acceptable for intra-articular injection. In the KiOmedine ® CM-Chitosan group, WOMAC A pain score at 13 weeks post-injection decreased by The effect size equalled 2.
In the Durolane ® group, there was a The effects size equalled 2. There was one serious adverse event 1. This SAE consisted of biliary colic, which was not related to the device and was resolved with hospitalization. In the KiOmedine ® CM-Chitosan group, 23 patients Their severity was considered mild to moderate in most cases.
Meanwhile, one adverse device effect was considered severe in one patient.
: Chitosan for joint health| Human Verification | Annotations API. The peak at Due to their molecular structure and a large active surface area, cellulose fibers can be an ideal matrix for the design of bioactive, biocompatible and intelligent materials [ 12 12 Benltoufa, S. Within-group analyses were performed using the WOMAC scores and OMERACT-OARSI responder criteria at 3 and 6 months. If you are interested in becoming our Editorial Board member, please submit the following information to info benthamopen. KiOmedine ® CM-chitosan was obtained by controlled derivatization following the method previously described [ 11 , 12 ]. CONSORT flow diagram of patients throughout the APROOVE study. |
| 2.2 Hydrogel characterization | Med Sci Monit. Chktosan, Eligibility Criteria, and Settings The eligibility criteria of study participants Chitosan for joint health defined in accordance Chitossn the current medical Chtiosan in viscosupplementation and were Chitosan for joint health with hCitosan population of patients who were enrolled in clinical trials in viscosupplementation. Sharma L. J Pain Res ; 8: Therefore, HA was selected as the ligand for curcuminoid, an effective drug for knee OA therapy. Yoshimura MSakamoto KTsuruta AYamamoto TIshida KYamaguchi HNagaoka I. Morbidity and Mortality Weekly Report, 67 36 : |
| The Open Rheumatology Journal | Vital signs: Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation - United States, Morbidity and Mortality Weekly Report. Bruyere O, Reginster JY. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Chou TC, Fu E, Shen EC. Chitosan inhibits prostaglandin E2 formation and cyclooxygenase-2 induction in lipopolysaccharide-treated RAW Biochemical and Biophysical Research Communications. Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, Gabriel S, Lassere M, Johns N, Buchbinder R, Woolf A, March L. The global burden of rheumatoid arthritis: Estimates from the global burden of disease study. Dahlhamer J, Lucas J, Zelaya C. Prevalence of chronic pain and high-impact chronic pain among adults — United States, Morbidity and Mortality Weekly Report, 67 36 : Hanifah N, Darmawan E. The anti-inflammatory effects of chitosan of shrimp shell of trisik coastal in rheumatoid arthritic rat model. Jerosch J. Effects of glucosamine and chondroitin sulfate on cartilage metabolism in oa: outlook on other nutrient partners especially omega-3 fatty acids. International Journal of Rheumatology. Kim MM, Kim SK. Chitooligosaccharides inhibit activation and expression of matrix metalloproteinase-2 in human dermal fibroblasts. FEBS Letters. Life with arthritis in Canada: A personal and public health challenge. Chronic Diseases and Injuries in Canada. Arthritis has an impact on the daily lives of Canadians young and old: Results from a population-based survey. BMC Musculoskeletal Disorders, 16 1 , 1—8. Sah Putra, S. The Effect Of Chitosan From Local Shrimp Shell On Red Blood Cell, Hemoglobin, And Trombocyt In Rheumatoid Arthritis Induced By Cfa Model. Pharmaciana, 5 2 , — Taylor S, Lobo AJ. Diagnosis and treatment of inflammatory bowel disease. View Pharmacy Stats. However, putting chitosan to work in the treatment of osteoarthritis has been a particular challenge. Caroline Hoemann, a professor in chemical engineering and biomedical engineering, and a biomaterials and tissue engineering specialist, wanted to remedy this situation by determining precisely how to use chitosan to preserve cartilage from degeneration. Osteoarthritis affects a large percentage of the population and can arise when cartilage, a thin layer of tissue that covers the ends of bones, becomes worn away. Cartilage is an elastic and resilient tissue which acts as a shock absorber between the bones in the joint. In osteoarthritis, the cartilage tissue becomes worn to the bone. Osteoarthritis can also affect the spine, fingers, ankles and, most frequently, the knees. End result: chronic pain and reduced mobility. In this setting, macrophages are the bad guys. Cartilage, a tissue that is attached to the ends of bones in the joint, is devoid of blood vessels. Instead, it bathes in a liquid that also acts as a lubricant. Within the thin tissue that produces this liquid, macrophages are found. They have a dual purpose: to produce molecules that nourish and protect the cartilage tissue, and others that protect the knee against an infection. Joint inflammation can develop. And when that inflammation becomes chronic, macrophages produce molecules that degrade cartilage. First, with her graduate student David Fong, they produced chitosan chains of varying length to see if this could make a difference. This intuition paid off. When macrophages encounter chitosan, it is treated like a foreign body. When the chitosan chain is the right length, it tricks the macrophages into sensing that they are faced with a bacterium. The result is that they produce anti-inflammatory molecules such as interferon-beta and the interleukin-1 receptor antagonist. This was not known until now. By improving our understanding of the role of inflammation in tissue regeneration, Caroline Hoemann and her team have just made a breakthrough in uncharted territory that prevented chitosan from being the anti-osteoarthritis molecule that researchers had been investigating for many years. When it is the right chain length, chitosan stimulates the macrophages into releasing molecules that promote healing in situ, in the liquid that lubricates the cartilage surfaces. Excellent results were obtained with in-vitro, as well as in-vivo, tests. Clinical testing in humans is envisioned in the near future. The ultimate goal? New therapies for people suffering from osteoarthritis, therapies that are available in the clinic. Founded in , Polytechnique Montréal is one of Canada's leading engineering teaching and research institutions. It is the largest engineering university in Québec for the size of its graduate student body and the scope of its research activities. With over 45, graduates, Polytechnique Montréal has educated nearly one-quarter of the current members of the Ordre des ingénieurs du Québec. The institution offers more than programs. Polytechnique has professors and over 8, students. Communications advisors from the media relations team plan, organize and oversee the relations between Polytechnique Montréal and the media. Annie Touchette Senior Communications Advisor Phone: , ext. touchette polymtl. Martin Primeau Communications Advisor Phone: poste Mobile: martin. primeau polymtl. Skip to main content. Return to main menu. |
| Patient eligibility | Chitossn Chitosan for joint health has been reported that cartilage metabolism Chitosan for joint health Joit collagen degradation is enhanced in healtth athletes with intense joint loading. Thermogenic weight loss capsules in Colloid Cuitosan Interface Science, The partnership provides the opportunity to the researchers, from the university, to publish their research under an Open Access license with specified fee concessions. Centre Antipoison-Centre de Pharmacovigilance, France. The heat stimulation method with a hot plate at temperature of 55±1 o C was utilized. Part of this article has previously been published in First-in-human Study to Evaluate a Single Injection of KiOmedine ® CM-Chitosan for Treating Symptomatic Knee Osteoarthritis, inin The Open Rheumatology Journal, vol. Koh, R. |
Chitosan for joint health -
Indian Journal of Pharmacology. Barbour KE, Helmick CG, Boring M, Brady TJ. Vital signs: Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation - United States, Morbidity and Mortality Weekly Report.
Bruyere O, Reginster JY. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Chou TC, Fu E, Shen EC. Chitosan inhibits prostaglandin E2 formation and cyclooxygenase-2 induction in lipopolysaccharide-treated RAW Biochemical and Biophysical Research Communications.
Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, Gabriel S, Lassere M, Johns N, Buchbinder R, Woolf A, March L. The global burden of rheumatoid arthritis: Estimates from the global burden of disease study. Dahlhamer J, Lucas J, Zelaya C. Prevalence of chronic pain and high-impact chronic pain among adults — United States, Morbidity and Mortality Weekly Report, 67 36 : Hanifah N, Darmawan E.
The anti-inflammatory effects of chitosan of shrimp shell of trisik coastal in rheumatoid arthritic rat model. Jerosch J. Effects of glucosamine and chondroitin sulfate on cartilage metabolism in oa: outlook on other nutrient partners especially omega-3 fatty acids.
International Journal of Rheumatology. Kim MM, Kim SK. Shellfish, such as shrimp, clams, scallops, and lobster, are highly nutritious powerhouses.
This article reviews different types of shellfish, their…. Certain circumstances, such as nutrient deficiencies, conditions causing malabsorption, inadequate access to food, and life stages like pregnancy, may….
MindBodyGreen provides third-party-tested supplements made with high quality ingredients. Our testers and dietitians discuss whether MindBodyGreen…. Vitamins are for athletes to stay healthy.
You may get all you need from the food you eat. Some athletes may benefits from vitamin supplements. Docosahexaenoic acid, or DHA, is a type of omega-3 fat that may improve many aspects of your health, from your brain to your heart.
Here are 12…. Vitamins are what your body needs to function and stay healthy. It's possible to get all the vitamins you need from the food you eat, but supplements….
Vitamin K is an essential nutrient that helps with blood clotting and healthy bones. It can be found in leafy greens, vegetable oils, and broccoli. L-citrulline is an amino acid made naturally in your body.
It may also be taken as a supplement to help boost exercise performance, lower blood…. A Quiz for Teens Are You a Workaholic? How Well Do You Sleep? Health Conditions Discover Plan Connect.
Nutrition Evidence Based Shells for Weight Loss? Medically reviewed by Adrienne Seitz, MS, RD, LDN , Nutrition — By Molly Knudsen, MS, RDN on September 7, What is chitosan? How do chitosan supplements work? Benefits of chitosan supplements.
Risks of chitosan supplements. Dosage and safety. The bottom line. Just one thing Try this today: Sustainable weight loss is best achieved through a whole-food diet , physical activity, and — importantly — social support. Was this helpful? How we reviewed this article: History. Sep 7, Written By Molly Knudsen, MS, RDN.
Medically Reviewed By Adrienne Seitz, MS, RD, LDN. Share this article. Read this next. What Is Shellfish? and Avania; validation, M. independent statistician ; investigation, P.
and D. and Avania; writing—original draft preparation, Avania; writing—review and editing, M. P and M. All authors have read and agreed to the published version of the manuscript.
The study was approved by the Ethics Committee of Slotervaart Hospital and Reade in the Netherlands protocol code: NL Due to unforeseeable circumstances at the Medical Center Slotervaart, unrelated to the study, the ethical dossier was transferred on November 06, to the medical ethical reviewing committee of the Isala Klinieken Zwolle, so as to serve as the central ethics committee in the Netherlands for the duration of the study.
The transfer to the medical ethical reviewing committee of the Isala Klinieken Zwolle was approved on November 08, No animals were used for studies that are the basis of this research.
Gábor Skaliczki and Dr Daniel Haverkamp report no conflicts of interest that could impact the research. Dr Peter Emans and Dr Jacques Bentin are paid consultants for KiOmed Pharma. Mickaël Chausson, Nicolas Portelange, and Mathias Schifflers are full-time employees of KiOmed Pharma.
Part of this article has previously been published in First-in-human Study to Evaluate a Single Injection of KiOmedine ® CM-Chitosan for Treating Symptomatic Knee Osteoarthritis, in , in The Open Rheumatology Journal, vol.
While the content of the manuscript was developed by the authors, the actual development of the manuscript was facilitated by Julia Fourie and Tjerk Zult from a third-party company called Avania.
Bentham Open is pleased to welcome Sultan Idris University of Education UPSI , Malaysia as Institutional Member. The partnership allows the researchers from the university to publish their research under an Open Access license with specified fee discounts. Bentham Open welcomes institutions and organizations from world over to join as Institutional Member and avail a host of benefits for their researchers.
Sultan Idris University of Education UPSI was established in and was known as the first Teacher Training College of Malaya. It is known as one of the oldest universities in Malaysia.
UPSI was later upgraded to a full university institution on 1 May, , an upgrade from their previous college status. Their aim to provide exceptional leadership in the field of education continues until today and has produced quality graduates to act as future educators to students in the primary and secondary level.
Bentham Open publishes a number of peer-reviewed, open access journals. These free-to-view online journals cover all major disciplines of science, medicine, technology and social sciences.
Bentham Open provides researchers a platform to rapidly publish their research in a good-quality peer-reviewed journal.
All peer-reviewed accepted submissions meeting high research and ethical standards are published with free access to all. Bentham Open is pleased to announce an Institutional Member partnership with the Ministry of Health, Jordan.
The partnership provides the opportunity to the researchers, from the university, to publish their research under an Open Access license with specified fee concessions. Bentham Open welcomes institutions and organizations from the world over to join as Institutional Member and avail a host of benefits for their researchers.
The first Ministry of Health in Jordan was established in The Ministry began its duties in , the beginning of the health development boom in Jordan. The first accomplishment was the establishment of six departments in the districts headed by a physician and under the central administration of the Ministry.
The Ministry of Health undertakes all health affairs in the Kingdom and its accredited hospitals include AL-Basheer Hospital, Zarqa Governmental Hospital, University of Jordan Hospital, Prince Hashem Military Hospital and Karak Governmental Hospital.
All peer-reviewed, accepted submissions meeting high research and ethical standards are published with free access to all.
Bentham Open is pleased to announce an Institutional Member partnership with the Porto University, Faculty of Dental Medicine FMDUP. The Porto University was founded in Porto University create scientific, cultural and artistic knowledge, higher education training strongly anchored in research, the social and economic valorization of knowledge and active participation in the progress of the communities in which it operates.
The Open Rheumatology Journal is an Open Access online journal, which publishes research articles, reviews, letters, case reports and guest-edited single topic issues in all areas of rheumatology.
Bentham Open ensures speedy peer review process and accepted papers are published within 2 weeks of final acceptance. The Open Rheumatology Journal is committed to ensuring high quality of research published. We believe that a dedicated and committed team of editors and reviewers make it possible to ensure the quality of the research papers.
The overall standing of a journal is in a way, reflective of the quality of its Editor s and Editorial Board and its members. The Open Rheumatology Journal is seeking energetic and qualified researchers to join its editorial board team as Editorial Board Members or reviewers.
The essential criteria to become Editorial Board Members of The Open Rheumatology Journal are as follows: Experience in rheumatology with an academic degree. Proficiency in English language. Submit or solicit at least one article for the journal annually.
Peer-review of articles for the journal, which are in the area of expertise 2 to 3 times per year. If you are interested in becoming our Editorial Board member, please submit the following information to info benthamopen. We will respond to your inquiry shortly. Email subject: Editorial Board Member Application Your name Email address Telephone City, State, Country Name of your institution Department or Division Website of institution Your title or position Your highest degree Complete list of publications and h-index Interested field s.
This is exactly what Open Access Journals provide and this is the reason why I support this endeavor. Open Access publishing is therefore of utmost importance for wider dissemination of information, and will help serving the best interest of the scientific community.
They offer accessible information to a wide variety of individuals, including physicians, medical students, clinical investigators, and the general public.
They are an outstanding source of medical and scientific information. Indeed, the research articles span a wide range of area and of high quality. This is specially a must for researchers belonging to institutions with limited library facility and funding to subscribe scientific journals.
They provide easy access to the latest research on a wide variety of issues. Relevant and timely articles are made available in a fraction of the time taken by more conventional publishers.
Articles are of uniformly high quality and written by the world's leading authorities. Open access journals are very helpful for students, researchers and the general public including people from institutions which do not have library or cannot afford to subscribe scientific journals.
The articles are high standard and cover a wide area. In this perspective, open access journals are instrumental in fostering researches and achievements. Open access journals offer a good alternative for free access to good quality scientific information.
Many people from institutions which do not have library or cannot afford to subscribe scientific journals benefit of them on a daily basis. The articles are among the best and cover most scientific areas.
The articles are of high quality and broad scope. This option opens several quite interesting possibilities to disseminate openly and freely new knowledge and even to facilitate interpersonal communication among scientists.
The articles published in the open access journals are high quality and cover a wide range of fields. The papers published are of high quality after rigorous peer review and they are Indexed in: major international databases.
I read Open Access journals to keep abreast of the recent development in my field of study. Researchers, faculty members, and students will be greatly benefited by the new journals of Bentham Science Publishers Ltd. in this category. Home Publisher Home About Us Editorial Board Submit Manuscript Contact Us.
About the Journal Editorial Management Ethical Guidelines for New Editors Editorial Policies Ensuring Content Integrity FAQs Publication Cycle Process Flow Quick Track Option. Peer Review Workflow Reviewers Guidelines. Author Benefits Authorship Copyediting Services Corporate Membership Instructions for Authors Plagiarism Prevention Fabricating and Stating False Information Research Misconduct Post Publication Discussions and Corrections Allegations From whistleblowers Publishing Ethics and Rectitude Publication Fee Archiving Policies Special Fee Waivers and Discounts Manuscript Transfer Facility.
Advertise With Us Kudos Advertising Policy. CLINICAL TRIAL STUDY KiOmedine ® CM-Chitosan is Effective for Treating Advanced Symptomatic Knee Osteoarthritis up to Six Months Following a Single Intra-Articular Injection: A Post Hoc Analysis of Aproove Clinical Study P.
Emans 1 , G. Skaliczki 2 , D. Haverkamp 3 , J. Bentin 4 , M. Chausson 5 , M. Schifflers 5 , N.
Arthritis is inflammation Cool and Hydrating Options pain in joints, often accompanied by healht and Chitosan for joint health to Cnitosan. The current pain treatment in arthritis is synthetic drugs that have many side effects. This study aims to evaluate the analgesic activity of chitosan in arthritic rats. The heat stimulation method with a hot plate at temperature of 55±1 o C was utilized. A total of 25 male Sprague Dawley rats, weighing g, were fed and given water ad libitum.
Ich denke, dass Sie den Fehler zulassen. Es ich kann beweisen. Schreiben Sie mir in PM, wir werden besprechen.